drugset / Trial / NCT02712957

A Proof-of-Concept Study Assessing NEO6860 in Osteoarthritis Pain

NCT02712957

Phase 2 Completed 54 enrolled Neomed Institute
RandomizedCrossoverDouble-blindTreatment

Summary

The purpose of this study is to assess NEO6860, a modality selective TRPV1 antagonist, in patients with pain associated with osteoarthritis of the knee.

Timeline

Start
2016-03
Primary completion
2016-11-17
Completion
2016-11-24

Drugs

EvaluationDrugModalityDoseRoute
Subject NEO6860 Small molecule 500 mg Oral
Comparator Naproxen Small molecule 500 mg Oral

Indications